Heart Failure News and Research RSS Feed - Heart Failure News and Research

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.
Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

A new clinical trial is testing the feasibility and efficiency of a doctor in New York City remotely performing long-distance, tele-robotic ultrasound exams over the Internet on patients in Chicago. [More]
Findings could help design tailor-made drugs to treat blood pressure

Findings could help design tailor-made drugs to treat blood pressure

One in three Americans has high blood pressure, a long-term constriction of arteries that can lead to coronary heart disease, heart failure and stroke. [More]
Record number of abstracts submitted to Heart Failure 2015

Record number of abstracts submitted to Heart Failure 2015

A record number of abstracts have been submitted to the world's leading heart failure congress, promising more original science than ever before. [More]
WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

With a $450,000 grant from the National Institutes of Health, researchers at Worcester Polytechnic Institute will analyze how mechanical forces and cellular growth factors affect the growth and development of human heart valves to advance the long-term goal of using tissue engineering to develop replacement valves that are more natural and longer-lasting than current replacement valves. [More]
IUPUI researcher awarded NIH grant to study neuroscience underlying obstructive sleep apnea

IUPUI researcher awarded NIH grant to study neuroscience underlying obstructive sleep apnea

Sleep apnea affects an estimated 25 million adults in the United States and is associated with increased risk of hypertension, stroke, health attack and heart failure. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
Pulmonary Hypertension Center at RI Hospital receives PHA accreditation

Pulmonary Hypertension Center at RI Hospital receives PHA accreditation

The Pulmonary Hypertension Center at Rhode Island Hospital is one of the nation's first centers of its kind to be accredited by the Pulmonary Hypertension Association. For those affected by pulmonary hypertension (PH), accreditation assures them and their providers that they have access to the most advanced care available in the country. [More]
CiRA, Takeda collaborate to develop clinical applications of iPS cells

CiRA, Takeda collaborate to develop clinical applications of iPS cells

Center for iPS Cell Research Application of Kyoto University and Takeda Pharmaceutical Company Limited announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. [More]
HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint. [More]
Ancient natural compound can protect the heart from hypertrophy

Ancient natural compound can protect the heart from hypertrophy

A natural compound derived from the bark of the magnolia tree, can protect the heart from hypertrophy, a thickening of cardiac muscle often caused by chronic high blood pressure that can lead to heart failure, researchers report in the April 14 issue of the online journal Nature Communications. [More]
Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension. [More]
Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates. [More]
Latest findings regarding nitric oxide offer new avenues to save lives

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Gratitude in heart attack patients improves cardiac health

Gratitude in heart attack patients improves cardiac health

Recognizing and giving thanks for the positive aspects of life can result in improved mental, and ultimately physical, health in patients with asymptomatic heart failure, according to research published by the American Psychological Association. [More]
HeartWare International gets approval to market HeartWare Ventricular Assist System in Canada

HeartWare International gets approval to market HeartWare Ventricular Assist System in Canada

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from Health Canada, the country's federal department responsible for helping Canadians maintain their health, to market the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. [More]
Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

The Cedars-Sinai Heart Institute completed 120 adult heart transplants and two adult heart-lung transplants in 2014, setting a new national standard for the most adult heart transplants performed in a single year. [More]
Changes in height can affect risk of coronary heart disease

Changes in height can affect risk of coronary heart disease

The shorter you are- the more your risk of coronary heart disease. That's the key finding of a new study led by the University of Leicester which discovered that every 2.5 inches change in your height affected your risk of coronary heart disease by 13.5%. For example, compared to a 5ft 6inch tall person, a 5 foot tall person on average has a 32% higher risk of coronary heart disease because of their relatively shorter stature. [More]
Medication adherence interventions for heart failure patients

Medication adherence interventions for heart failure patients

Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs. [More]
Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites. [More]
Advertisement